Drug intelligence / Profile preview

NTZ-1034

Development stage: Preclinical
Lead developer: NTZ Lab
Modality: Small Molecules

Overview

NTZ-1034 (formerly known as PSB-1434) is a selective monoamine oxidase B (MAO-B) inhibitor small molecule being developed by NTZ Lab. It is currently in the preclinical stage for the treatment of central nervous system disorders, including Parkinson's disease, Alzheimer's disease, dementia, and depression. The drug works by blocking the MAO-B enzyme, which is responsible for the oxidative deamination of monoamine neurotransmitters such as dopamine in the brain. By inhibiting this enzyme, NTZ-1034 aims to increase neurotransmitter levels and provide neuroprotective effects.

Targets

MAOB (Monoamine oxidase B)

Beyond the preview

Go deeper on NTZ-1034.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTZ-1034.

Explore the full profile